Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2682939 | 1.00 | CYP3A4 (0.40) | CYP3A4FFAR3 | |
| SCHEMBL2682021 | 1.00 | CYP3A4 (0.40) | CYP3A4FFAR3 | |
| SCHEMBL15125244 | 0.85 | FFAR3 (0.37) | FFAR3 | |
| SCHEMBL26835343 | 0.85 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL3133271 | 0.85 | FFAR3 (0.37) | FFAR3 | |
| SCHEMBL2451197 | 0.85 | FFAR3 (0.37) | FFAR3 | |
| SCHEMBL7324549 | 0.84 | FFAR3 (0.33) | CYP3A4FFAR3 | |
| SCHEMBL29191746 | 0.82 | FFAR3 (0.34) | FFAR3 | |
| SCHEMBL29191745 | 0.82 | FFAR3 (0.34) | FFAR3 | |
| SCHEMBL11040604 | 0.82 | FFAR3 (0.34) | FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-9914721-B2 | Use of benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-03-13 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170001985-A1 | USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-01-05 | — | — | US | disclosed |
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2635571-B1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2635571-B1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8921372-B2 | Inhibitors of hepatitis C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-30 | — | — | US | disclosed |
| WO-2012061552-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CYP3A4 594/4885FFAR3 1630/4885 |
| US-20170001985-A1 | USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES | TPP1, TPP2, IL4I1 | CYP3A4 2897/4885FFAR3 3754/4885 |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | HAVCR2, SLC10A1, HDGF | CYP3A4 876/4885FFAR3 3552/4885 |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | CYP3A4 375/4885FFAR3 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.